SCHEMBL3634728

SCHEMBL3634728

CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 5/20 0.71
ALDH1A1 P00352 4/20 0.69
MEN1 O00255 3/20 0.69
BLM P54132 3/20 0.69
KMT2A Q03164 3/20 0.69
FAAH O00519 3/20 0.69
MAPT P10636 3/20 0.69
HPGD P15428 3/20 0.69
TDP1 Q9NUW8 3/20 0.69
KDM4E B2RXH2 2/20 0.69
USP2 O75604 2/20 0.69
CYP3A4 P08684 2/20 0.69
ALOX15 P16050 2/20 0.69
RECQL P46063 2/20 0.69
HSD17B10 Q99714 2/20 0.69
POLB P06746 1/20 0.69
APEX1 P27695 1/20 0.69
PMP22 Q01453 1/20 0.69
GPR18 Q14330 1/20 0.69
SLC6A5 Q9Y345 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3634730 1.00 CNR1 (0.71) CNR1ALDH1A1MEN1BLMKMT2A
SCHEMBL18736051 0.96 MEN1 (0.67) CNR1ALDH1A1MEN1BLMKMT2A
SCHEMBL23280891 0.95 MEN1 (0.69) CNR1ALDH1A1MEN1BLMKMT2A
SCHEMBL30581393 0.95 MEN1 (0.69) CNR1ALDH1A1MEN1BLMKMT2A
SCHEMBL6285516 0.95 MEN1 (0.69) CNR1ALDH1A1MEN1BLMKMT2A
SCHEMBL23193125 0.93 TOP1 (0.61) CNR1ALDH1A1MEN1BLMKMT2A
SCHEMBL23280934 0.91 ALDH1A1 (0.62) CNR1ALDH1A1MEN1KMT2AHPGD
SCHEMBL23027735 0.89 TERT (0.63) MEN1BLMKMT2AFAAHMAPT
SCHEMBL379107 0.89 TERT (0.63) MEN1BLMKMT2AFAAHMAPT
SCHEMBL2771719 0.89 TERT (0.63) MEN1BLMKMT2AFAAHMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12194080-B2 Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-01-14 US disclosed
EP-3368157-B1 METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF METABOLIC DISORDERS USING PM20D1 AND N-LIPIDATED AMINO ACIDS DANA FARBER CANCER INST INC (US) 2022-06-29 EP disclosed
EP-3297621-A1 A METHOD FOR TREATING PERIPHERAL INFLAMMATORY DISEASE Dublin City University (IE) 2018-03-28 EP disclosed
US-20160375071-A1 COMPOSITIONS AND METHODS COMPRISING YEAST ORGANISMS AND LIPID EXTRACTS THEREOF R.F. TECHNOLOGY CONSULTANTS, INC. 2016-12-29 US disclosed
WO-2016185025-A1 A METHOD FOR TREATING PERIPHERAL INFLAMMATORY DISEASE DUBLIN CITY UNIVERSITY (IE) 2016-11-24 WO disclosed
WO-2016185025-A1 A METHOD FOR TREATING PERIPHERAL INFLAMMATORY DISEASE DUBLIN CITY UNIVERSITY (IE) 2016-11-24 WO disclosed
EP-3095444-A1 A METHOD OF TREATING PERIPHERAL INFLAMMATORY DISEASE Dublin City University (IE) 2016-11-23 EP disclosed
EP-3095444-A1 A METHOD OF TREATING PERIPHERAL INFLAMMATORY DISEASE Dublin City University (IE) 2016-11-23 EP disclosed
EP-2150820-A1 ANALYSIS METHOD Surescreen Diagnostics Limited (GB) 2010-02-10 EP disclosed
WO-2008122805-A1 ANALYSIS METHOD SURESCREEN DIAGNOSTICS LIMITED (GB) 2008-10-16 WO disclosed